BioTelemetry Inc (BEAT, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. BioTelemetry Inc provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Its segments are healthcare, technology and research. BioTelemetry Inc has a market cap of $2.21 billion; its shares were traded at around $66.43 with a P/E ratio of 170.33 and P/S ratio of 5.98.
For the last quarter BioTelemetry Inc reported a revenue of $100.0 million, compared with the revenue of $81.02 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $399.5 million, an increase of 39.3% from last year. For the last five years BioTelemetry Inc had an average revenue growth rate of 23.6% a year.
The reported diluted earnings per share was $1.2 for the year, an increase of -326.4% from previous year. The BioTelemetry Inc had a decent operating margin of 18.03%, compared with the operating margin of 10.35% a year before. The 10-year historical median operating margin of BioTelemetry Inc is -3.95%. The profitability rank of the company is 6 (out of 10).
At the current stock price of $66.43, BioTelemetry Inc is traded at 275.1% premium to its historical median P/S valuation band of $17.71. The P/S ratio of the stock is 5.98, while the historical median P/S ratio is 1.59. The stock gained 101.00% during the past 12 months.
CFO Recent Trades:
- Executive VP & CFO Heather C Getz sold 10,590 shares of BEAT stock on 02/01/2019 at the average price of $70.41. The price of the stock has decreased by 5.65% since.
- Executive VP & CFO Heather C Getz sold 93,383 shares of BEAT stock on 01/29/2019 at the average price of $70.06. The price of the stock has decreased by 5.18% since.
For the complete 20-year historical financial data of BEAT, click here.
